BioCentury
ARTICLE | Clinical News

Conjuchem DAC:GLP-1 Phase II data

July 15, 2004 7:00 AM UTC

Conjuchem (TSE:CJC) said in an international Phase II trial in 206 Type II diabetes patients, DAC:GLP-1 reduced glycemia by 30% compared to untreated control patients, the primary endpoint (p<0.05). G...